• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Xeris Biopharma Holdings, Inc. - Common Stock (NQ:XERS)

    6.630 +0.260 (+4.08%)
    Streaming Delayed Price Updated: 4:00 PM EDT, May 7, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Xeris Biopharma Holdings, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    News headline image
    Xeris (XERS) Q1 2026 Earnings Call Transcript ↗
    Xeris (XERS) Q1 2026 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    Xeris Biopharma (NASDAQ:XERS) Achieves First Profit, Beats Q1 Estimates with 95% Recorlev Surge ↗
    Via Chartmill
    News headline image
    Xeris Biopharma Reports First Quarter 2026 Financial Results
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    News headline image
    Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) Surges on Strong Q4 Earnings and Robust 2026 Outlook ↗
    Via Chartmill
    News headline image
    Earnings Scheduled For November 6, 2025 ↗
     
    Via Benzinga
    News headline image
    Earnings Scheduled For August 7, 2025 ↗
     
    Via Benzinga
    News headline image
    Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    News headline image
    Xeris Biopharma (XERS) Q4 2025 Earnings Transcript ↗
    Xeris Biopharma (XERS) Q4 2025 Earnings Transcript 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    News headline image
    Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    News headline image
    Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    News headline image
    Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    News headline image
    Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    News headline image
    Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday ↗
    One of the company's key drugs won't be challenged by a competing medication anytime soon. 
    Via The Motley Fool
    The market is filled with gapping stocks in Wednesday's session. ↗
    Via Chartmill
    News headline image
    Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    News headline image
    Xeris Biopharma (XERS) Q3 2025 Earnings Transcript ↗
    Xeris Biopharma (XERS) Q3 2025 Earnings Transcript 
    Via The Motley Fool
    News headline image
    XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) Posts Record Q3 2025 Revenue but Misses Analyst Estimates ↗
    Xeris Biopharma posts record Q3 2025 revenue of $74.4M, up 37% YoY, but misses earnings estimates. The company raises full-year guidance. 
    Via Chartmill
    News headline image
    Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    News headline image
    Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    News headline image
    Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    News headline image
    Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    News headline image
    Xeris (XERS) Q2 Revenue Jumps 49% ↗
    Via The Motley Fool
    News headline image
    Traders are paying attention to the gapping stocks in Thursday's session. ↗
    Let's have a look at the gap up and gap down stocks in today's session. 
    Via Chartmill
    News headline image
    XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) Surges 12% After Q2 Earnings Beat and Raised Revenue Guidance ↗
    Xeris Biopharma (XERS) Q2 2025 results beat estimates with $71.5M revenue (+48.8% YoY) and narrower losses. Stock surged 12.2% pre-market as Recorlev sales soared 136%. Raised full-year guidance to... 
    Via Chartmill
    Topics Earnings
    News headline image
    Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    News headline image
    Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    News headline image
    XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) – A Strong Growth Candidate Meeting Minervini’s Criteria ↗
    XERIS Biopharma (XERS) meets Minervini’s Trend Template with strong technicals and high growth momentum, including 47.9% quarterly revenue growth and a 93.95 Relative Strength score. 
    Via Chartmill
    News headline image
    Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.